Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients

被引：10
|
作者：
Kumar, Lakshin [1 ]
Dasgupta, Sayan [2 ]
Murray-Krezan, Cristina [3 ]
Singh, Nina [4 ,5 ]
Rakita, Robert M. [1 ]
Fisher, Cynthia E. [1 ,6 ]
Limaye, Ajit P. [1 ]
机构：
[1] Univ Washington, Dept Med, Div Allergy & Infect Dis, 1959 NE Pacific St, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[3] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA
[4] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA
[5] Univ Pittsburgh, Pittsburgh, PA USA
[6] Univ Washington, 1959 NE Pacific St, Seattle, WA 98195 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2024年 / 78卷 / 03期
基金：
美国国家卫生研究院;
关键词：
liver transplant; immunocompromised host; viral infections; cytomegalovirus; antiviral therapy;
D O I：
10.1093/cid/ciad643
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
In a post-hoc analysis of the association of CMV DNAemia with long-term mortality in a randomized trial of CMV preemptive therapy vs. antiviral prophylaxis in D+R- liver transplant recipients, post-intervention CMV DNAemia was associated with increased mortality after adjusting for study arm. Graphical Abstract This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/association-of-cmv-dnaemia-with-long-term-mortality-in-a-randomized-trial-of-preemptive-therapy-pet-and-antiviral-prophylaxis-ap-for-prevention-of-cmv-disease-in-high-risk-donor-seropositive-recipient-se-2480b1a4-e573-43a6-973b-94ea264eed04
引用
收藏
页码：719 / 722
页数：4
相关论文
共 50 条
  • [31] Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients
    Kletzmayr, J
    Kreuzwieser, E
    Watkins-Riedel, T
    Berlakovich, G
    Kovarik, J
    Klauser, R
    TRANSPLANTATION, 2000, 70 (08) : 1174 - 1180
  • [32] Cytomegalovirus (CMV) immunoglobulin does not confer any additional protection along with newer antiviral prophylaxis for prevention of CMV infection in high risk liver transplant recipients.
    Fernandez, H
    Nadadi, S
    Palmieri, D
    Lally, A
    Charpentier, K
    Brown, M
    Hoffman, M
    Israel, J
    Polio, J
    Hull, D
    Ranga, KV
    LIVER TRANSPLANTATION, 2006, 12 (05) : C61 - C61
  • [33] Incidence of CMV Disease in High-Risk Liver Transplant Recipients on Low Dose Valganciclovir Prophylaxis
    Tischer, S.
    Park, J.
    Stuckey, L.
    Kaul, D.
    Sonnenday, C.
    Fontana, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 221 - 222
  • [34] Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease
    Reusing Jr, Jose O.
    Feitosa, Emanoela B.
    Agena, Fabiana
    Pierrotti, Ligia C.
    Azevedo, Luiz S. F.
    Kotton, Camille N.
    David-Neto, Elias
    TRANSPLANT INFECTIOUS DISEASE, 2018, 20 (05)
  • [35] Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: A multicenter, open-label study
    Snydman, DR
    Falagas, ME
    Avery, R
    Perlino, C
    Ruthazer, R
    Freeman, R
    Rohrer, R
    Fairchild, R
    O'Rourke, E
    Hibberd, P
    Werner, BG
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (04) : 2571 - 2575
  • [36] Examining valganciclovir prophylaxis duration among high-risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort
    Imlay, Hannah
    Dumitriu Carcoana, Allison O.
    Fisher, Cynthia E.
    Wong, Beatrice
    Rakita, Robert M.
    Fishbein, Daniel P.
    Limaye, Ajit P.
    TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [37] Pre-emptive therapy prevents development of cytomegalovirus (CMV) disease and associated chronic allograft nephropathy (CAN) following high risk CMV donor seropositive/recipient seronegative renal transplants.
    Bakran, A
    Sunil, S
    Sinha, S
    Tong, W
    Cuevas, L
    Powis, S
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 425A - 425A
  • [38] Transplant related mortality following allogeneic BMT in CMV seropositive donor/recipient pairs is increased despite efficacious prevention of CMV disease by pre-emptive therapy with ganciclovir
    Broers, A
    Henzen-Logmans, S
    Kuenen-Boumeester, V
    de la Riviére, GB
    Van der Holt, B
    Löwenberg, B
    Cornelissen, JJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 13 - 13
  • [39] A practical guide to real-world implementation of pre-emptive therapy for Cytomegalovirus disease prevention in high-risk seronegative liver transplant recipients with seropositive donors
    Heldman, Madeleine R.
    Dunn, Bailey
    Clemens, Evan
    Henderson, Megan
    Fisher, Cynthia E.
    Rakita, Robert M.
    Kling, Catherine E.
    Limaye, Ajit P.
    TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (03)
  • [40] Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients
    Hasegawa, Jumpei
    Hatakeyama, Shuji
    Wakai, Sachiko
    Omoto, Kazuya
    Okumi, Masayoshi
    Tanabe, Kazunari
    Mieno, Makiko
    Shirakawa, Hiroki
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 65 : 50 - 56
12345